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A B S T R A C T
Purpose
Earlier studies evaluating the effect on quality of life (QoL) of localized prostate cancer interven-
tions included patients receiving adjuvant hormone therapy, which could have affected their
outcomes. Our objective was to compare the QoL impact of the three most common primary
treatments on patients who were not receiving adjuvant hormonal treatment.
Patients and Methods
This was a prospective study of 435 patients treated with radical prostatectomy, external-beam
radiotherapy, or brachytherapy. QoL was assessed before and after treatment with the Short
Form-36 and the Expanded Prostate Cancer Index Composite. Differences between groups were
tested by analysis of variance. Distribution of outcome at 3 years was examined by stratifying
according to baseline status. Generalized estimating equation models were constructed to assess
the effect of treatment over time.
Results
Compared with the brachytherapy group, the prostatectomy group showed greater deterioration
on urinary incontinence and sexual scores but better urinary irritative-obstructive results (18.22,
13.19, and6.38, respectively, at 3 years; P .001). In patients with urinary irritative-obstructive
symptoms at baseline, improvement was observed in 64% of those treated with nerve-sparing
radical prostatectomy. Higher bowel worsening (2.87, P  .04) was observed in the external
radiotherapy group, with 20% of patients reporting bowel symptoms.
Conclusion
Radical prostatectomy caused urinary incontinence and sexual dysfunction but improved pre-
existing urinary irritative-obstructive symptoms. External radiotherapy and brachytherapy caused
urinary irritative-obstructive adverse effects and some sexual dysfunction. External radiotherapy
also caused bowel adverse effects. Relevant differences between treatment groups persisted for
up to 3 years of follow-up, although the difference in sexual adverse effects between brachyther-
apy and prostatectomy tended to decline over long-term follow-up. These results provide valuable
information for clinical decision making.
J Clin Oncol 28:4687-4696. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Prostate cancer is the most common cancer in men
in the United States1 and the secondmost common
in the European Union.2 Increased detection (inci-
dence) associated with the widespread use of
prostate-specificantigen testinghas enableddiagno-
sis at earlier disease stages.1,3 A recent systematic
review of localized prostate cancer treatment effec-
tiveness4 concluded that all treatments caused uri-
nary, bowel, or sexual dysfunction with different
frequency, duration, and severity, but they
were insufficiently characterized to facilitate clin-
ical recommendations.
The occurrence of relevant treatment adverse
effects combined with otherwise good results in
terms of cancer control5-9 have led to a growing
interest in evaluating the impact of treatment on
quality of life (QoL). Previous longitudinal QoL
studies10-15 included patients receiving hormone
therapy, particularly as an adjunct to external or
interstitial radiotherapy, which could have affected
the results obtained for these primary treatments.
Recently, Sanda et al14 showed that adjuvant
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androgen suppression exacerbated the adverse effects of external ra-
diotherapy or brachytherapy on sexuality and vitality. Therefore, evi-
dence is needed on the impact of the commonprimary treatments for
localized prostate cancer on patients’ QoL when used without hor-
mone therapy.
Most longitudinal studies have only followed patients for up to
116-18 or 2 years,13-15,19,20 whereas treatment adverse effects and QoL
maychange furtherwith longer follow-up.10,11,21,22 Long-termstudies
couldbeparticularly relevant inexternalor interstitial radiotherapy, as
adverse effects might appear later as a result of chronic damage to
adjacent tissues. Patients treated with external radiotherapy showed
later worsening in incontinence21 and sexual dysfunction.11,21 How-
ever, the only long-term follow-up study that included brachyther-
apy showed recoveries21 in urinary irritative symptoms and
bowel function.
The objective of this study was to compare the QoL impact of
radical prostatectomy, three-dimensional external-beam radiother-
apy, and prostate brachytherapy on patients with localized prostate
cancer who were not receiving adjuvant hormonal treatment, from
pretreatment to 3 years after the intervention.
PATIENTS AND METHODS
Study Design and Participants
This was a prospective study of a clinically localized prostate cancer
cohort treated with radical prostatectomy, external-beam radiotherapy,
or brachytherapy.
Participants included in the Spanish Multicentric Study of Clinically
Localized Prostate Cancer were followed for 3 years after treatment. Details of
the study are described elsewhere.15 Briefly, consecutive outpatients from 10
Spanish hospitals were enrolled from April 2003 to March 2005. Inclusion
criteria were stages T1 or T223 and no previous transurethral prostate resec-
tion. For the purpose of this analysis, patients who received neoadjuvant or
adjuvant hormonal therapy were excluded. Decisions on treatment options
were made jointly by patients and physicians. The surgery group underwent
radical retropubic prostatectomy, and the nerve-sparing technique was
used at the surgeon’s discretion. External-beam radiation was 3D confor-
mal. Treatment was delivered with 1.8 Gy to 2.0 Gy daily fractions to a mean
doseof 73.7Gy(standarddeviation [SD]5.0) to theprostateplanning target
volume. In the brachytherapy group, participants received 125I, and the pre-
scription dose was 144 Gy to the reference isodose (100%) according to the
TaskGroup 43 (TG-T43).24 Themedian dose of D90 andV100%was 158Gy
and 93%, respectively.
Research protocols were approved by the ethics review boards of the
participating hospitals, and written informed consent was required for each
participant according to the 2000 revision of the Declaration of Helsinki.
Measurement Instruments
Participants’ clinical characteristics evaluated at baseline included: T
stage, prostate-specific antigen (PSA), Gleason histological grading scores,
prostate volume, and reported chronic conditions. The definition ofD’Amico
et al5 was used to classify patients according to risk group. QoL instruments
were administered centrally by telephone interviews before and 1, 3, 6, 12, 24,
and 36months after treatment.
Generic andprostate cancer–specificQoLquestionnaireswere included.
The Short Form-36 Health Survey (SF-36) version 225,26 was used. Scores for
the two summary components (physical andmental component scores) were
calculated using the recommended standardized procedure.25,26 The Ex-
pandedProstateCancer IndexComposite (EPIC)27 includes50 itemsgrouped
into two urinary subscales (incontinence and irritative-obstructive) and three
summary scores (bowel, sexual, andhormonal), with scores ranging from0 to
100. The International Prostate Symptom Score28,29 contains seven items
measuring urinary obstruction, with scores ranging from 0 (no symptoms) to
35. With the exception of the International Prostate Symptom Score, higher
scores indicate better QoL.
In addition to the EPIC continuous scores, we classified distressful levels
of symptoms following the strategy proposed byTalcott et al22,30 “No relevant
problem” describes a patient with no distressful symptoms, “small to moder-
ate problem” describes a patient reporting at least one distressful symptom,
and“severeproblem”describes apatientwith at least one extremelydistressful
symptom.Within each EPIC domain, only the severity itemswere considered
to construct this classification. These items and the level of distress associated
with each response category are specified in the Appendix Table A1 (on-
line only).
Statistical Analysis
Between-group differences on QoLmean scores at each assessment and
changes in mean QoL scores (from baseline to 3 years after treatment) were
tested using analysis of variance and Tukey’s studentized range for post
hoc comparisons.
To facilitate the interpretability of results, the percentages of patients
with no relevant, small to moderate, and severe problems at 3 years after
treatment were shown in bar charts. To examine the effect of pretreatment
symptomsontheoccurrenceof treatmentadverseeffects, thesebarchartswere
constructed after we stratified patients according to their symptoms severity
at baseline.13
To assess the effect of treatment on QoL and adverse effects over time
while accounting for correlation among repeated measures, we constructed
separate generalized estimating equation (GEE) models for each EPIC scale
and for the SF-36 physical component score (included as dependent vari-
ables). Age, risk group, and prostate volume at baseline were included in the
models as adjusting factors. So as not to assume a linear association, we
included time in the model as a categorical variable with four categories:
pretreatment (reference), and months 12, 24, and 36. Regarding treatment,
brachytherapy patients were used as the reference group in these models, and
interactions between treatment and time were also included. The statistical
analyses were carried out using SPSS 12.0 and SAS 9.1 software.
RESULTS
A total of 179 patients were excluded as a result of having received
hormone treatment, resulting in a final sample of 435 patients (Table
1). There were statistically significant differences by treatment group
at baseline for age, PSA, T stage, risk group, and prostate volume.
Those receiving radical prostatectomy tended to be younger, whereas
the lowest values for PSA, T stage, risk group, and prostate volume
were seen in the prostate brachytherapy group. However, pretreat-
ment QoL scores were similar among treatment groups.
Figure 1 shows QoL mean scores over the follow-up period by
treatment group. Scores on the SF-36 mental component were quite
stable, whereas a slight decrease was observed on the physical compo-
nent. In the radical prostatectomy group, there was a notable decline
in the urinary incontinence and sexual scores after treatment, with
subsequent partial recovery. Sexual recovery was higher after nerve-
sparing radical prostatectomy (NSRP) than after non–nerve-sparing
radicalprostatectomy(NNSRP).Comparedwithpatients treatedwith
surgery, the brachytherapy and external radiotherapy groups showed
significantly lower (worse) urinary irritative-obstructive and bowel
scores, respectively, during the last 2 years of follow-up.Meanchanges
inQoL scores frombaseline to 3 years of follow-upare shown inTable
2. Sexual and urinary incontinence deterioration was greater in pa-
tients treated with radical prostatectomy (mean change, 23.9 and
25.1, respectively) than in the other groups, though this group
showed fewer changes in urinary irritative-obstructive symptoms.
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Table 1. Patient Characteristics and Quality-of-Life Scores at Pretreatment Evaluation and Response Rate at Each Follow-Up Assessment
Variable
Radical Prostatectomy
External-Beam
Radiotherapy Brachytherapy
PNo. % No. % No. %
Participants 123 28.3 127 29.2 185 42.5
Clinical characteristics
Age, years  .001†‡
Mean 64.2 69.5 66.0
SD 5.5 5.4 7.0
PSA, ng/mL  .001†‡
Mean 8.0 8.2 6.8
SD 3.3 4.7 2.1
Gleason score .150
Mean 6.9 5.9 5.9
SD 6.4 1.0 5.3
T stage
1 82 66.7 73 57.5 152 82.2  .001†‡
2 41 33.3 53 41.7 33 17.8
Unknown 0 0 1 0.8 0 0.0
Risk group
Low 52 42.3 72 57.1 165 89.2  .001‡
Intermediate 67 54.5 44 34.9 19 10.3
High 4 3.3 10 7.9 1 0.5
Prostate volume, cm3  .001
Mean 52.4 45.2 34.0
SD 27.7 25.3 9.8
No. of chronic conditions .486
Mean 2.33 2.5 2.3
SD 1.5 1.8 1.6
Quality-of-life scores
SF-36
PCS .016‡
Mean 53.1 52.4 54.2
SD 6.2 5.8 4.9
MCS .141
Mean 54.1 54.6 53.3
SD 5.9 5.2 6.7
EPIC
Urinary
Incontinence .404
Mean 94.5 96.3 96.1
SD 15.1 9.9 11.1
Irritative/obstructive .304
Mean 93.4 95.5 94.4
SD 11.1 9.5 11.1
Bowel .036
Mean 97.9 97.8 96.5
SD 3.7 4.5 7.2
Sexual .246
Mean 59.0 54.1 55.9
SD 23.5 23.2 23.3
Hormonal .197
Mean 94.0 95.7 95.5
SD 9.1 8.4 8.0
IPSS .221
Mean 6.8 5.8 5.7
SD 6.1 5.6 5.3
(continued on following page)
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Bowel andhormonaldeteriorationweremainlyobserved in the radio-
therapy group (mean change,3.2 and5.0, respectively).
To expand the information represented by mean score changes,
Figure 2 shows the distribution of patients with no relevant, small to
moderate, and severe problems at 3 years according to baseline status,
which indicates the proportion of patients who improved, preserved
status, or worsened. Considering patients with no relevant sexual
problem at baseline, approximately 40% of patients in the external
and interstitial radiotherapy groups had preserved pretreatment sex-
ual status compared with less than 10% in the surgery group; the
proportion of patients with any severe problem after NNSRP (83%)
was higher than after NSRP (64%). Among patients with any small to
moderate sexual problem at baseline, deterioration was observed in
89% of patients after NNSRP and 67% after NSRP, compared with
50% for the brachytherapy group.
Because not enough patients (n  9-18) had severe urinary or
hormonal problems at baseline for a separate analysis, they were ana-
lyzed jointly with those patients who reported small to moderate
problems. At 3 years, almost 75% of patients in the external and
interstitial radiotherapy groups had preserved pretreatment urinary
continence, compared with 45% of NSRP and 31% of NNSRP pa-
tients. Brachytherapy resulted in the highest proportion of patients
who experienced urinary irritative-obstructive symptoms (35%),
whereas in patients with pretreatment small to severe urinary
irritative-obstructive symptoms, improvement over baseline was ob-
served in64%of those treatedwithNSRP.Mostof thepatientsdidnot
present relevant bowel problems at baseline, and 23% of patients
treatedwithexternal radiotherapy reportedbowelproblemsat 3years.
The proportion of patients with hormonal adverse effects was similar
among treatment groups, approximately 20% in those with no rele-
vant problem at baseline.
Table 3 shows the results from the GEE models constructed to
assess treatment impact at different follow-up evaluations. In the
urinary incontinence model, patients in the prostatectomy group
showed significantly greater deterioration than those in the brachy-
therapy reference group throughout follow-up (20.10,17.33,
and 18.22 at 1st, 2nd, and 3rd year, respectively; P  .001). On
irritative-obstructive symptoms, the difference from pretreatment
(mean, 93.4; SD, 11.1) was significantly lower in the prostatectomy
group at each year of follow-up (  5.14, 5.56, and 6.38,
respectively for 1st, 2nd, and 3rd year), with positive coefficients indi-
cating less deterioration from pretreatment than among patients in
the brachytherapy group. In the sexual summary model, scores for
patients in thebrachytherapy groupwere lower (worse) thanpretreat-
ment, and deterioration increased ( 5.74, 7.26 and 10.03, respec-
tively, at the end of the 1st, 2nd, and 3rd years). Deterioration from
pretreatment was significantly larger in the prostatectomy group
throughout follow-up (P .001), thoughdifferenceswith thebrachy-
therapy group decreased somewhat over time ( 21.30, 19.74 and
13.19, respectively, at the 1st, 2nd, and 3rd year).
Standard categorization of effect size (ES) was applied to
understand the magnitude or clinical importance of these GEE 
coefficients. ES was calculated as adjusted mean differences () di-
videdby SDat baseline. The guidelines define anESof 0.2 as small, 0.5
as moderate, and 0.8 as large.31,32 For example, the ES for significant
differences between surgery and brachytherapy on the EPIC urinary
incontinence, sexual, and urinary irritative-obstructive symptoms
( 18.2, 13.2, and6.4, respectively, at the 3rd year) was large for
incontinence (ES, 1.2), and moderate for sexuality and urinary
irritative-obstructive symptoms (ES,0.6 and0.6).
DISCUSSION
This comparative study of the three primary treatments for localized
prostate cancer when used without hormone therapy shows a
distinctive pattern of adverse effects for these treatments. Radical
prostatectomy caused considerable urinary incontinence and sexual
dysfunction, interstitial and external radiotherapy caused moderate
urinary irritative-obstructive symptoms and sexual dysfunction, and
external radiotherapy also produced moderate bowel-related ad-
verse effects. Long-termmodifications of adverse effects, such as an
increase in urinary-related adverse effects after external radiother-
apy or sexual adverse effects with brachytherapy, tended to reduce
Table 1. Patient Characteristics and Quality-of-Life Scores at Pretreatment Evaluation and Response Rate at Each Follow-Up Assessment (continued)
Variable
Radical Prostatectomy
External-Beam
Radiotherapy Brachytherapy
PNo. % No. % No. %
Response rate (quality-of-life questionnaires)
Pretreatment 123 100.0 127 100.0 185 100.0
Month 1 66 53.7 43 33.9 100 54.1 .001‡
Month 3 114 92.7 117 92.1 172 93.0 .961
Month 6 107 87.0 108 85.0 163 88.1 .732
Month 12 111 90.2 112 88.2 169 91.4 .654
Month 24 111 90.2 108 85.0 161 87.0 .457
Month 36 109 88.6 100 78.7 155 83.8 .107
NOTE. One-way analysis of variance for continuous variables among the three treatment groups; Tukey studentized range post hoc comparisons. The response
rate at month 1 was lower, resulting in scheduled evaluations at month 1 and 3 having a high concentration of interviews in a short period of time. Evaluations at
month 3 were prioritized.
Abbreviations: SD, standard deviation; PSA, prostate-specific antigen; SF-36, Medical Outcomes Study 36-Item Short Form; PCS, physical component score; MCS,
mental component score; EPIC, Expanded Prostate Cancer Index Composite; IPSS, International Prostate Symptom Score.
P  .005 for radical prostatectomy v external-beam radiotherapy.
†P  .005 for radical prostatectomy v brachytherapy.
‡P  .005 for brachytherapy v radiotherapy.
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Fig 1. Mean quality-of-life (QoL) scores by treatment group—radical prostatectomy, external-beam radiotherapy, and brachytherapy—for Short Form-36 (SF-36)
physical component score (PCS; A); SF-36 mental component score (MCS; B); Expanded Prostance Cancer Index Composite (EPIC) urinary incontinence (C), urinary
obstructive (D), bowel (E), sexual (F), and hormonal (G) domains; and International Prostate Symptom Score (IPSS). The surgery group is shown separately, as a solid
line for nerve-sparing radical prostatectomy (NSRP) and as a dashed line for non–nerve-sparing radical prostatectomy (NNSRP), for EPIC urinary, sexual, and hormonal
domains. One-way analysis of variance of QoL scores among the three treatment groups for each follow-up assessment. Tukey studentized range post hoc
comparisons: (*) P  .05 for radical prostatectomy versus external-beam radiotherapy; (†) P  .05 for radical prostatectomy versus brachytherapy; (‡) P  .05 for
brachytherapy versus radiotherapy; (§) P  .05 for non–nerve-sparing radical prostatectomy only; () P  .05 for nerve-sparing radical prostatectomy only.
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differences between treatments over time. However, these modifi-
cations were only slight and did not imply a real change in the
characteristic pattern.
Sexual dysfunction was a common adverse effect of treatments,
but it was also the most frequent concurrent symptom previous to
treatment. In our sample, half of the patients presented severe sexual
problems at baseline, almost 30% presented small to moderate prob-
lems, and only 22% did not present any relevant sexual problem.
Differences in sexual adverse effects between patients with normal or
poorpretreatment sexual functioningwere reportedpreviously.11,13,22
These studies showed that adverse effectsweremore severe in patients
withbetter pretreatment sexual functioning, possibly because patients
with sexual dysfunction may leave little margin for additional,
treatment-related worsening. Consistent with this finding, out of the
patients treated with surgery in our study, more than 90% of those
without any relevant sexual problems at baseline presented sexual
adverse effects, compared with 67% of patients with small to mod-
erate sexual problems at baseline who received nerve-sparing pro-
cedures. Brachytherapy presented lower levels of sexual adverse
effects than prostatectomy, with approximately half of patients
worsening, independently of whether they experienced no relevant
or small to moderate pretreatment sexual problems. These results
provide useful evidence to inform patients regarding expected
treatment adverse effects according to their levels of pretreatment
sexual functioning.
Regarding urinary treatment–related effects, the prostatectomy
group showed worse adverse effects for incontinence, but better re-
sults on urinary irritative-obstructive symptoms compared with
brachytherapy at 3 years after treatment. The prostatectomy group
presented approximately twice as many patients with urinary incon-
tinence adverse effects (69% for NNSRP and 54% for NSRP), com-
pared with 25% of those treated with external or interstitial
radiotherapy without relevant pretreatment incontinence problems.
Amongpatientswith urinary obstructive-irritative symptoms at base-
line, improvement was observed in 64% of patients treated with
NSRP, 44%with brachytherapy, and 28%with external radiotherapy.
Our results confirm previously reported improvement in urinary
obstruction-irritation inpatients treatedwith prostatectomy, and also
for those treated with radiotherapy.14,22 It has been argued that exter-
nal and interstitial radiotherapy may lead to small improvements
becauseof a reduction inprostate size.Thispotential clinical benefitof
radical prostatectomy may simplify clinical decision making for pa-
tients who have pre-existing irritative-obstructive urinary symptoms.
Only the group of patients treated with external radiotherapy
presented a statistically significant moderate worsening of bowel
symptoms (ES, 0.6). If we analyze these results at the individual
level,33 8% of patients presented severe bowel problems, and 15%
small tomoderateones, at 3years. Finally, onlya smalldeterioration in
hormonal summary scores (ES, 0.2)wasobserved at 3 years.Although
statistically significant differences in changes between treatment
groups were observed in the bivariate analysis, they were not signifi-
cant in the GEEmodel. Consistent with this finding, the distribution
of patients with hormonal adverse effects was similar in the three
treatment groups.
With regard to the long-termmodification of adverse effects, it is
noticeable that the patterns of urinary adverse effects in external ra-
diotherapy and brachytherapy became more similar over time. Dur-
ing the first 2 years, positive coefficients in the incontinence and
irritative-obstructive models indicated that patients treated with ex-
ternal radiotherapy had better results than those treated with brachy-
therapy. Nevertheless, the differences were no longer statistically
significant at year 3 (5.2 and .6 at 2 and 3 years, respectively, for
incontinence). Worsening incontinence among patients treated with
external radiotherapywas also reported byMiller et al21 fromyear 2 to
year6of follow-up.The reductionof thedifferences in sexualdysfunc-
tion between the prostatectomy and brachytherapy groups was also
noteworthy (19.7 and13.2 at year 2 and year 3, respectively).
This reduction could be partly explained by the long-term sexual
Table 2. Mean (and standard deviation) Changes in Quality-of-Life Scores From Pretreatment to 3-Year Follow-Up by Treatment Group
Score
Radical Prostatectomy
Conformal External
Radiotherapy Brachytherapy
P
Non–Nerve Sparing Nerve Sparing
Mean SD Mean SD Mean SD Mean SD
SF-36 PCS
PCS 3.9 8.7 3.2 7.4 6.2 8.3 5.2 7.6 .167
MCS 0.2 9.7 2.2 7.8 0.7 9.1 1.3 8.8 .215
EPIC
Urinary incontinence 26.3 28.8 21.4 25.2 6.7 17.8 7.4 20.7  .001†
Urinary irritative/obstructive 1.8 14.4 7.0 13.1 5.6 15.9 5.9 21.0 .002‡†‡
Bowel 1.3 3.1 1.7 4.5 3.2 11.1 0.3 11.8 .006§
Sexual 23.4 25.7 25.3 28.2 10.6 22.4 9.9 23.5  .001†
Hormonal 1.7 12.8 2.4 15.5 5.0 14.1 2.0 10.7 .034‡
IPSS 0.9 7.0 2.7 4.7 0.4 6.3 1.1 7.0 .017†‡
One-way analysis of variance for the differences in quality-of-life scores from baseline to 3-year follow-up, by treatment group. Tukey studentized range post hoc
comparisons.
Abbreviations: SD, standard deviation; SF-36, Medical Outcomes Study 36-Item Short Form; PCS, physical component score; MCS, mental component score; EPIC,
Expanded Prostate Cancer Index Composite; IPSS, International Prostate Symptom Score.
P  .05 for radical prostatectomy v radiotherapy.
†P  .05 for radical prostatectomy v brachytherapy.
‡P  .05 for nerve-sparing radical prostatectomy only.
§P  .05 for non–nerve-sparing radical prostatectomy only.
P  .05 for brachytherapy v radiotherapy.
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Fig 2. Distribution of patients with no relevant problems (light gray), small to moderate problems (light tan), or severe problems (light blue) at 3 years after treatment,
stratified by baseline symptoms on Expanded Prostate Cancer Index Composite (A) sexual, (B) urinary incontinence, (C) urinary irritative-obstructive, (D) bowel, and (E)
hormonal domains. EPIC, Expanded Prostate Cancer Index Composite; NNSRP, non–nerve-sparing radical prostatectomy; NSRP, nerve-sparing radical prostatectomy;
EBRT, external-beam radiation therapy; BT, brachytherapy; RP, radical prostatectomy. Sample size was not large enough to perform bowel outcome analysis of the
groups with small to moderate problems (n  14) and severe problems (n  5) at baseline separately.
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Table 3. Generalized Estimating Equation Models of the Association Between Treatment Groups and Clinical Variables, With SF-36 Physical Component
Score and EPIC Scores at Each Year of Follow-Up
Variable
SF-36 Physical Component
Score EPIC Urinary Incontinence
EPIC Urinary Irritative-
Obstructive
 SE P  SE P  SE P
Intercept 63.29 2.53  .0001 89.1 9.29  .0001 98.12 5.99  .0001
Age 0.14 0.04  .0001 0.08 0.14 .552 0.06 0.09 .507
Prostate volume 0 0.01 .979 0.03 0.04 .363 0 0.02 .993
Risk group
Low ref. ref. ref. ref. ref. ref.
Intermediate-high 0.26 0.63 .682 2.73 1.77 .122 1.17 1.11 .29
Treatment group (differences at baseline)
Brachytherapy ref. ref. ref. ref. ref. ref.
Radiotherapy 1.67 0.71 0.018 0.64 1.45 .66 0.83 1.41 .554
Prostatectomy 1.75 0.78 0.026 2.8 1.92 .146 1.27 1.55 .412
Interaction brachytherapy  time
(change from baseline)
Baseline ref. ref. ref. ref. ref. ref.
12 months 1.73 0.4  .0001 3.75 1.34 .005 4.62 1.29 0
24 months 3.26 0.56  .0001 7.58 1.58  .0001 4.8 1.4 .001
36 months 4.93 0.57  .0001 6.85 1.61  .0001 5.73 1.64 .001
Interaction radiotherapy  time
(difference from brachytherapy)
Baseline ref. ref. ref. ref. ref. ref.
12 months 0.17 0.7 .811 2.15 1.85 .245 4.21 1.64 .01
24 months 0.44 0.91 .631 5.16 2.07 .013 2.77 1.87 .139
36 months 0.75 1.03 .467 0.63 2.48 .798 0.06 2.42 .981
Interaction prostatectomy  time
(difference from brachytherapy)
Baseline ref. ref. ref. ref. ref. ref.
12 months 0.01 0.78 .985 20.1 3.31  .0001 5.14 1.87 .006
24 months 0.13 0.94 .889 17.33 3.32  .0001 5.56 2 .006
36 months 0.64 1.05 .544 18.22 3.08  .0001 6.38 2.16 .003
Variable
EPIC Bowel Summary EPIC Sexual Summary EPIC Hormonal Summary
 SE P  SE P  SE P
Intercept 93.74 2.74  .0001 106.53 9.98  .0001 85.39 3.98  .0001
Age 0.04 0.04 .283 0.77 0.15  .0001 0.16 0.06 .005
Prostate volume 0 0.01 .672 0.01 0.04 .78 0.01 0.02 .71
Risk group
Low ref. ref. ref. ref. ref. ref.
Intermed.-high 1.07 0.51 .035 0.9 (2.21) .685 0.3 0.83 .72
Treatment group (differences at baseline)
Brachytherapy ref. ref. ref. ref. ref. ref.
Radiotherapy 0.88 0.76 .245 1.51 2.96 .61 0.63 1.15 .586
Prostatectomy 1.12 0.72 .12 0.4 3.15 .9 1.5 1.13 .185
Interaction brachytherapy  time
(change from baseline)
Baseline ref. ref. ref. ref. ref. ref.
12 months 0.51 0.68 .454 5.74 1.72 .001 0.14 0.58 .815
24 months 1.19 0.61 .051 7.26 1.84  .0001 0.51 0.75 .498
36 months 0.2 0.91 .827 10.03 1.85  .0001 1.88 0.86 .03
Interaction radiotherapy  time
(difference from brachytherapy)
Baseline ref. ref. ref. ref. ref. ref.
12 months 2.99 1.13 .008 1.06 2.57 .68 0.68 0.88 .437
24 months 4.03 1.2 .001 1.67 2.88 .563 0.14 1.16 .905
36 months 2.87 1.4 .04 1.23 3.07 .689 2.7 1.7 .112
Interaction prostatectomy  time
(difference from brachytherapy)
Baseline ref. ref. ref. ref. ref. ref.
12 months 0.19 0.96 .843 21.3 3.16  .0001 0.9 1.46 .539
24 months 0.46 0.73 .53 19.74 3.34  .0001 1.07 1.37 .432
36 months 1.15 0.98 .239 13.19 3.28  .0001 1.97 1.66 .234
NOTE. Time was included in the model as a categorical variable with four categories so as not to assume a linear association: baseline (reference), month 12, month
24, and month 36. Interaction variables between each treatment group and time were included: for interaction with brachytherapy, the coefficients refer to the
changes from baseline; and for the radiotherapy and prostatectomy groups, the coefficients refer to the difference from the brachytherapy group (reference group)
on the changes from baseline.
Abbreviations: SF-36, Short Form-36; EPIC, Expanded Prostate Cancer Index Composite; ref., reference.
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deterioration observed in brachytherapy patients (  7.3 and
10.0 at year 2 andyear3).Chenet al22 also reporteda slight tendency
to deteriorate on this parameter in the brachytherapy group, com-
paredwith a tendency toward recovery in the prostatectomy group. A
longer follow-upwould be needed to confirmwhether the worsening
observed in our sample from the 2nd to the 3rd year of follow-up
indicates a true trend toward later occurrence of sexual dysfunction
with brachytherapy treatment.
Some limitationsof this studyshouldbe taken intoaccount.First,
this is an observational study, and participants were not randomly
assigned to treatment groups. However, randomized clinical trials
have presented considerable difficulties in these patients.34 Baseline
differences in clinical characteristics between treatment groups in our
sample couldbe attributed to theobservational designof the study.To
account for the possible effect of clinical differences, we adjustedGEE
models by the relevant clinical characteristics. Age, risk group, or
prostate volumeshowed little impacton treatmentoutcomes. Second,
nerve-sparing techniques were not widely applied in our study (28%
of patients treated with prostatectomy), and our findings from the
GEEmodel for theprostatectomygroupasawholecouldoverestimate
their adverse sexual effects. Nevertheless, large sexual adverse effects
for prostatectomy treatment were also shown by other studies that
included high proportions of patients who received nerve-sparing
procedures.13,14 Third, improvements observed in urinary inconti-
nence, hormonal function, and sexual function, regardless of which
treatmentwas applied,were generally experiencedby a lownumberof
patients, andmay be partially explained by the regression to themean
phenomenon. Unexpected improvements have also been reported in
previous studies.11,35
This study provides (to our knowledge) novel long-term results
onQoL and adverse effects for the three commonprimary treatments
in patients with localized prostate cancer who were not receiving
adjuncthormonal treatment.Furthermore, the interpretationstrategy
addressedat the individual andaggregate levels followedhereprovides
complementary useful information.Mean scores of treatment groups
indicate results on average and facilitate comparison with other stud-
ies because it is the most usual approach. However, it could be a
challenge to communicate the evidence to patients in a meaningful
way. In fact, clinical interpretability of QoL scores has been identified
as one of the barriers to the use of this type of measure.36 The inter-
pretation approach at an individual level shows the percentages of
patientswithadverse effects, andcould facilitate clinical interpretation
and the transmission of information to patients.
Inconclusion,ourfindings suggest that adverseeffectsof external
and interstitial radiotherapy could increase beyond 2 years of follow-
up.Nevertheless, urinary irritative-obstructive symptoms, sexual dys-
function, and bowel-related adverse effects associated with interstitial
or external radiotherapy were still moderate at 3 years of follow-up,
whereas radical prostatectomywas associatedwith substantial urinary
incontinence and sexual dysfunction over the same period. These
results could provide relevant information to characterize adverse
effects of primary treatments and facilitate shared clinical decision
making between patients and professionals.
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CORRECTIONS
Author Corrections
The November 20, 2010, special article by Pappo et al,
entitled “Infrequent Tumor Initiative of the Children’s Oncol-
ogy Group: Initial Lessons Learned and Their Impact on Future
Plans” (J Clin Oncol 28:5011-5016, 2010), contained an error.
In the Introduction section, the second sentence was given as:
“Indeed,theRareDiseaseActof20021 definesararediseaseasonethat
affects fewer than 200,000 persons per year in the United States.”
Whereas it should have read:
“Indeed, the Rare Disease Act of 20021 defines a rare dis-
ease as one that affects fewer than 200,000 persons in the United
States.”
The authors apologize to the readers for the mistake.
DOI: 10.1200/JCO.2011.34.7351
■ ■ ■
The December 20, 2010, article by Kunitake et al, enti-
tled “Routine Preventive Care and Cancer Surveillance in
Long-Term Survivors of Colorectal Cancer: Results From
National Surgical Adjuvant Breast and Bowel Project Proto-
col LTS-01” (J Clin Oncol 28:5274-5279, 2010), contained
an error.
The first initial of the seventh author’s name was inad-
vertently omitted. The author’s name was given as Lawrence
Wickerham and should have been D. Lawrence Wickerham.
The authors apologize to the readers for the mistake.
DOI: 10.1200/JCO.2011.34.7369
■ ■ ■
Journal Corrections
The November 1, 2010, article by Pardo et al, entitled
“Quality-of-Life Impact of Primary Treatments for Localized
Prostate Cancer in Patients Without Hormonal Treatment”
(J Clin Oncol 28:4687-4696, 2010), contained an error.
In the legend of Figure 1, the colors of the lines correspond-
ing to the treatments were inadvertently omitted. The corrected
legend is reprinted below in its entirety.
Mean quality-of-life (QoL) scores by treatment group—
radical prostatectomy (gold), external-beam radiotherapy
(gray), and brachytherapy (blue)—for (A) Short Form-36 (SF-
36) physical component score (PCS); (B) SF-36 mental compo-
nent score (MCS); (C) Expanded Prostate Cancer Index
Composite (EPIC) urinary incontinence, (D) urinary obstruc-
tive, (E) bowel, (F) sexual, and (G) hormonal domains; and
International Prostate Symptom Score (IPSS). The surgery
group is shown separately, as a solid line for nerve-sparing
radical prostatectomy (NSRP) and as a dashed line for non–
nerve-sparing radical prostatectomy (NNSRP), for EPIC uri-
nary, sexual, and hormonal domains. One-way analysis of
variance of QoL scores among the three treatment groups for
each follow-up assessment. Tukey studentized range post hoc
comparisons: (*) P  .05 for radical prostatectomy versus
external-beam radiotherapy; (†) P  .05 for radical prostatec-
tomy versus brachytherapy; (‡) P  .05 for brachytherapy
versus radiotherapy; (§)P .05 for NNSRP only; ()P .05 for
NSRP only.
Journal of Clinical Oncology apologizes to the authors and
readers for the mistake.
DOI: 10.1200/JCO.2011.34.7377
■ ■ ■
The May 10, 2010, article by Ziepert et al, entitled “Stan-
dard International Prognostic Index Remains a Valid Predictor
of Outcome for Patients With Aggressive CD20 B-Cell Lym-
phoma in the Rituximab Era” (J Clin Oncol 28:2373-2380,
2010), contained an error.
The institutional affiliation for Evelyn Kuhnt should have
been given as the Clinical Trial Centre, Universita¨t Leipzig,
Leipzig, Germany.
Journal of Clinical Oncology apologizes to the authors and
readers for the mistake.
DOI: 10.1200/JCO.2011.34.7393
■ ■ ■
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